{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:23:22Z","timestamp":1789140202106,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001512","name":"National Brain Tumor Society","doi-asserted-by":"publisher","award":["AWD 21-004061"],"award-info":[{"award-number":["AWD 21-004061"]}],"id":[{"id":"10.13039\/100001512","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U19 CA264362"],"award-info":[{"award-number":["U19 CA264362"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD099543"],"award-info":[{"award-number":["R01HD099543"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1124\/jpet.124.002170","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T15:00:22Z","timestamp":1714143622000},"page":"100014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Central nervous system distributional kinetics of selected histone deacetylase inhibitors"],"prefix":"10.1016","volume":"392","author":[{"given":"Wenqiu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney C.","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael W.","family":"Sirianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Elmquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.124.002170_bib1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1186\/s12885-016-2886-9","article-title":"Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer","volume":"16","author":"Amin","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1124\/jpet.124.002170_bib2","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1158\/1078-0432.CCR-09-0547","article-title":"JNJ-26481585, a novel \u201csecond-generation\u201d oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity","volume":"15","author":"Arts","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.124.002170_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1124\/jpet.124.002170_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2020.152507","article-title":"Vorinostat is genotoxic and epigenotoxic in the mouse bone marrow cells at the human equivalent doses","volume":"441","author":"Attia","year":"2020","journal-title":"Toxicology"},{"key":"10.1124\/jpet.124.002170_bib5","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/jps.23258","article-title":"Species difference of esterase expression and hydrolase activity in plasma","volume":"101","author":"Bahar","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"issue":"2 Pt B","key":"10.1124\/jpet.124.002170_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.canlet.2014.09.049","article-title":"DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells","volume":"356","author":"Pont","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1124\/jpet.124.002170_bib7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s12032-014-0985-5","article-title":"Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience","volume":"31","author":"Bezecny","year":"2014","journal-title":"Med Oncol"},{"key":"10.1124\/jpet.124.002170_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2010.03.010","article-title":"Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition","volume":"78","author":"Blattmann","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1124\/jpet.124.002170_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/pbc.24724","article-title":"Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program","volume":"61","author":"Carol","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1124\/jpet.124.002170_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","article-title":"Modulation of radiation response by histone deacetylase inhibition","volume":"62","author":"Chinnaiyan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1124\/jpet.124.002170_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2018.10.012","article-title":"Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma","volume":"442","author":"Choi","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1124\/jpet.124.002170_bib12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"key":"10.1124\/jpet.124.002170_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/jpet.124.002170_bib14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.102.045260","article-title":"Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux","volume":"304","author":"Dai","year":"2003","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1124\/jpet.124.002170_bib15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1471-4159.2005.03098.x","article-title":"Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in\u00a0vitro, ex\u00a0vivo and in\u00a0vivo","volume":"93","author":"Ey\u00fcpoglu","year":"2005","journal-title":"J\u00a0Neurochem"},{"key":"10.1124\/jpet.124.002170_bib16","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1021\/jm900648x","article-title":"Hydroxamates: relationships between structure and plasma stability","volume":"52","author":"Flipo","year":"2009","journal-title":"J\u00a0Med Chem"},{"key":"10.1124\/jpet.124.002170_bib17","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1124\/jpet.124.002170_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF01066322","article-title":"Area method for the estimation of partition coefficients for physiological pharmacokinetic models","volume":"15","author":"Gallo","year":"1987","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"key":"10.1124\/jpet.124.002170_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"key":"10.1124\/jpet.124.002170_bib20","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.tips.2021.03.001","article-title":"Efflux limits tumor drug delivery despite disrupted BBB","volume":"42","author":"Griffith","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.124.002170_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1158\/1535-7163.MCT-17-0011","article-title":"Radiosensitization in\u00a0vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity","volume":"17","author":"Groselj","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.124.002170_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40478-020-00953-2","article-title":"Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients","volume":"8","author":"Guntner","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1124\/jpet.124.002170_bib23","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","article-title":"On the rate and extent of drug delivery to the brain","volume":"25","author":"Hammarlund-Udenaes","year":"2008","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.124.002170_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069964","article-title":"SAHA enhances synaptic function and plasticity in\u00a0vitro but has limited brain availability in\u00a0vivo and does not impact cognition","volume":"8","author":"Hanson","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/jpet.124.002170_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169485","article-title":"Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models","volume":"12","author":"Hennika","year":"2017","journal-title":"PloS One"},{"key":"10.1124\/jpet.124.002170_bib26","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1021\/acs.jmedchem.7b01444","article-title":"Controlling plasma stability of hydroxamic acids: A MedChem Toolbox","volume":"60","author":"Hermant","year":"2017","journal-title":"J\u00a0Med Chem"},{"key":"10.1124\/jpet.124.002170_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cbpa.2008.03.019","article-title":"Blood-brain barrier permeability considerations for CNS-targeted compound library design","volume":"12","author":"Hitchcock","year":"2008","journal-title":"Curr Opin Chem Biol"},{"key":"10.1124\/jpet.124.002170_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/js9803205","article-title":"MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening","volume":"88","author":"Irvine","year":"1999","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1124\/jpet.124.002170_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/neuonc\/nor017","article-title":"A\u00a0phase I\/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03","volume":"13","author":"Iwamoto","year":"2011","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.124.002170_bib30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: novel drugs for the treatment of cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.124.002170_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1124\/dmd.118.084210","article-title":"Brain distribution of a panel of epidermal growth factor receptor inhibitors using cassette dosing in wild-type and Abcb1\/Abcg2-Deficient Mice","volume":"47","author":"Kim","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.124.002170_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijpharm.2008.05.001","article-title":"In\u00a0vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors","volume":"361","author":"Konsoula","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1124\/jpet.124.002170_bib33","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/neuonc\/nou350","article-title":"Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma","volume":"17","author":"Lee","year":"2015","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.124.002170_bib34","article-title":"Comprehensive analysis of the differential expression and prognostic value of histone deacetylases in glioma","volume":"10","author":"Li","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1124\/jpet.124.002170_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/jpet.124.002170_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167081","article-title":"Quisinostat is a brain-penetrant radiosensitizer in glioblastoma","volume":"8","author":"Lo Cascio","year":"2023","journal-title":"JCI Insight"},{"key":"10.1124\/jpet.124.002170_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/jm0303655","article-title":"Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors","volume":"47","author":"Lu","year":"2004","journal-title":"J\u00a0Med Chem"},{"key":"10.1124\/jpet.124.002170_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/1471-2407-8-243","article-title":"Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain\u00a0tissue: class II and IV are hypoexpressed in glioblastomas","volume":"8","author":"Lucio-Eterovic","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1124\/jpet.124.002170_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1078-0432.CCR-09-1385","article-title":"Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of urviving levels","volume":"16","author":"Mahalingam","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.124.002170_bib40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.yjmcc.2010.11.009","article-title":"Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart","volume":"51","author":"McKinsey","year":"2011","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1124\/jpet.124.002170_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69102-y","article-title":"Comparing ultrafiltration and equilibrium dialysis to measure unbound plasma dolutegravir concentrations based on a design of experiment approach","volume":"10","author":"Metsu","year":"2020","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.124.002170_bib42","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","article-title":"Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity","volume":"11","author":"Munshi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.124.002170_bib43","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1158\/1535-7163.MCT-06-0022","article-title":"Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of \u03b3-H2AX foci","volume":"5","author":"Munshi","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.124.002170_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10637-012-9831-9","article-title":"Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines","volume":"31","author":"Muscal","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1124\/jpet.124.002170_bib45","first-page":"27","article-title":"A\u00a0simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J\u00a0Basic Clin Pharm"},{"key":"10.1124\/jpet.124.002170_bib46","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/neuonc\/noz089","article-title":"A\u00a0large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma","volume":"21","author":"Pak","year":"2019","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.124.002170_bib47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.124.002170_bib48","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3389\/fcell.2020.00546","article-title":"Histone deacetylase inhibitors in pediatric brain cancers: biological activities and therapeutic potential","volume":"8","author":"Perla","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1124\/jpet.124.002170_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11060-017-2724-1","article-title":"Phase I\/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas","volume":"137","author":"Peters","year":"2018","journal-title":"J\u00a0Neurooncol"},{"key":"10.1124\/jpet.124.002170_bib50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ccell.2016.03.002","article-title":"Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype","volume":"29","author":"Phoenix","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.124.002170_bib51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1242\/dmm.000976","article-title":"Mouse xenograft models vs GEM models for human cancer therapeutics","volume":"1","author":"Richmond","year":"2008","journal-title":"Dis Model Mech"},{"key":"10.1124\/jpet.124.002170_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol Oncol"},{"key":"10.1124\/jpet.124.002170_bib53","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/jps.21916","article-title":"Significance of protein binding in pharmacokinetics and pharmacodynamics","volume":"99","author":"Schmidt","year":"2010","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1124\/jpet.124.002170_bib54","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in\u00a0vivo\u00a0efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.124.002170_bib55","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/neuonc\/noab188","article-title":"Phase I\/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children\u2019s Oncology Group report","volume":"24","author":"Su","year":"2022","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.124.002170_bib56","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/j.bmcl.2004.03.063","article-title":"Thiol-based SAHA analogues as potent histone deacetylase inhibitors","volume":"14","author":"Suzuki","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.124.002170_bib57","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2174\/092986705774454706","article-title":"Non-hydroxamate histone deacetylase inhibitors","volume":"12","author":"Suzuki","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1124\/jpet.124.002170_bib58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/jpet.121.000845","article-title":"Brain distribution of berzosertib: An ataxia telangiectasia and rad3-related protein inhibitor for the treatment of glioblastoma","volume":"379","author":"Talele","year":"2021","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1124\/jpet.124.002170_bib59","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-0312","article-title":"A\u00a0phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors","volume":"19","author":"Venugopal","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.124.002170_bib60","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/neuonc\/noaa249","article-title":"Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-na\u00efve diffuse midline glioma models","volume":"23","author":"Vitanza","year":"2021","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.124.002170_bib61","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central nervous system multiparameter optimization desirability: Application in drug discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/jpet.124.002170_bib62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/jpet.124.002170_bib63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2012.11.018","article-title":"A\u00a0mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds","volume":"75","author":"Wang","year":"2013","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1124\/jpet.124.002170_bib64","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/jpet.124.002170_bib65","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijpharm.2012.12.011","article-title":"Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines","volume":"441","author":"Wang","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1124\/jpet.124.002170_bib66","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF02280763","article-title":"Drug-protein binding kinetics in patients with type I diabetes","volume":"43","author":"W\u00f6rner","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.124.002170_bib67","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1124\/jpet.124.002170_bib68","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/1078-0432.CCR-06-1261","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in\u00a0vitro and in\u00a0vivo","volume":"13","author":"Yin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.124.002170_bib69","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/jps.23557","article-title":"Propagation of error in ocular pharmacokinetic parameters estimate of azithromycin in rabbits","volume":"102","author":"You","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1124\/jpet.124.002170_bib70","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/jps.2600820718","article-title":"Estimation of variance for AUC in animal studies","volume":"82","author":"Yuan","year":"1993","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1124\/jpet.124.002170_bib71","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.123.001826","article-title":"CNS distribution of panobinostat in preclinical models to guide dosing for pediatric brain tumors","volume":"387","author":"Zhang","year":"2023","journal-title":"J\u00a0Pharmacol Exp Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524000636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524000636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.124.002170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:01:06Z","timestamp":1777420866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524000636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0022356524000636"],"URL":"https:\/\/doi.org\/10.1124\/jpet.124.002170","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central nervous system distributional kinetics of selected histone deacetylase inhibitors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.124.002170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100014"}}